Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.
Mihaela AldeaMarco TagliamentoArnauld BayleDamien VasseurVéronique VergéArianna MarinelloFrançois-Xavier DanlosFélix Blanc-DurandElsa BernardLuigi CerboneMaria Fernanda MoseleAline RennevilleJulien HadouxYohann LoriotMadona SakkalAurore VozyClementine SarkozyCristina SmolenschiClaudio NicotraPatricia Martin-RomanoClementine Boccon-GibodWafikaamira HabzaJulien LazaroviciSantiago PonceAntoine HollebecqueChristophe MarzacLudovic LacroixFabrice BarlesiFabrice AndreBenjamin BesseEtienne RouleauAntoine ItalianoJean-Baptiste MicolPublished in: JCO precision oncology (2023)
The incidental findings of high-risk CH through liquid biopsy may trigger diagnostic hematologic tests and reveal an occult hematologic malignancy. Patients should have a multidisciplinary case-by-case evaluation.
Keyphrases
- circulating tumor
- end stage renal disease
- cell free
- circulating tumor cells
- chronic kidney disease
- ejection fraction
- newly diagnosed
- genome wide
- ionic liquid
- single cell
- prognostic factors
- ultrasound guided
- peritoneal dialysis
- dna methylation
- gene expression
- patient reported outcomes
- quality improvement
- label free
- quantum dots